Month: May 2022

– More than 75 patients dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; planned global regulatory submissions on track for late 2022- -Initiated two new CTX001 Phase 3 clinical trials in pediatric patients with TDT and SCD- -Enrollment and dosing ongoing for CTX110™, targeting CD19+ B-cell malignancies; additional data expected to report in 2022- -Updates from ongoing CTX120™ and CTX130™ clinical trials anticipated in 1H2022- ZUG, Switzerland and CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the first quarter ended March 31, 2022. “I am pleased with the ongoing momentum across our broad portfolio of innovative gene therapy...

PHOENIX, May 09, 2022 (GLOBE NEWSWIRE) — Mesa Air Group, Inc. (NASDAQ: MESA) today reported second quarter fiscal 2022 financial and operating results. Financial Summary Q2:Pre-tax loss of $55.2 million, net loss of $42.8 million or $(1.19) per diluted share. Adjusted net loss1 of $10.3 million or $(0.29) per diluted share. Adjusted net loss excludes a $39.5 million (pre-tax) non-cash charge related to 12 CRJ aircraft held for sale.Quarter Highlights:Mesa took delivery of its third 737-400F freighter aircraft in the quarter. Added an additional E175 flight simulator.Fiscal Year Q2 Results: Mesa’s Q2 FY22 results reflect a net loss of $42.8 million, or $(1.19) per diluted share, compared to net income of $5.7 million, or $0.14 per diluted share for Q2 FY21. Mesa’s Q2 FY22 adjusted pre-tax loss1 was $13.1 million versus...

Expands HM43239 dose cohort at 160 mg Headway with luxeptinib “G3” formulation in patients Conference call and webcast at 5:00 pm ET today SAN DIEGO and TORONTO, May 09, 2022 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced financial results for the three months ended March 31, 2022 and provided a corporate update. The net loss for the quarter ended March 31, 2022 was $11.5 million ($0.12 per share) compared with $16.2 million ($0.18 per share) for the quarter ended March 31, 2021. Total cash and cash equivalents and investments as of March 31, 2022 were $69.5 million. Based on current operations, Aptose expects that cash on hand and...

Completed enrollment in ZEPHYRUS-1 Phase 3 study of pamrevlumab in idiopathic pulmonary fibrosis 1Q 2022 revenue of $60.8M, growth of 58% vs. 1Q 2021 Significant roxadustat volume growth in China in first quarter 2022 offsetting NRDL price reductionSAN FRANCISCO, May 09, 2022 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2022 and provided an update on the company’s recent developments. “We continue our progress in advancing pamrevlumab in three high value indications and are delighted to have completed enrollment of the ZEPHYRUS-1 Phase 3 study in idiopathic pulmonary fibrosis,” said Enrique Conterno, Chief Executive Officer, FibroGen. “In addition, roxadustat is off to a strong start in 2022 in China with significant year over year volume growth.” Recent Developments:Completed...

First Quarter Revenue Grew 11% versus Last Year to $63.0 millionFirst Quarter Retail Unit Sales of 2,270First Quarter F&I Revenue Grew 138% versus Last Year RICHMOND, Va., May 09, 2022 (GLOBE NEWSWIRE) — CarLotz, Inc. (the “Company” or “CarLotz”; NASDAQ: LOTZ), a leading consignment-to-retail used vehicle marketplace, today announced financial results for the first quarter ended March 31, 2022. First Quarter 2022 Financial ResultsNet revenue increased 11% to $63.0 million from $56.6 million in the same period in 2021 Retail unit sales were 2,270 compared to 2,554 in the same period in 2021 Finance & insurance revenue increased 138% to $3.7 million from $1.6 million in the same period in 2021 Gross profit was $2.1 million compared to $2.0 million in the same period in 2021 Retail GPU was $827 compared to $1,182 in the...

Gevo to Host Conference Call Today at 4:30 p.m. EDT/2:30 p.m. MDT ENGLEWOOD, Colo., May 09, 2022 (GLOBE NEWSWIRE) — Gevo, Inc. (NASDAQ: GEVO) (“Gevo”, the “Company”, “we”, “us” or “our”) today announced financial results for the first quarter of 2022 and recent corporate highlights. Recent Corporate HighlightsOn January 31, 2022, Gevo announced that it had begun the process of bringing its dairy manure-based renewable natural gas (“RNG”) project online in northwest Iowa and once this facility has reached steady-state production levels of approximately 355,000 MMBTU, its evaluation period by the California Air Resource Board and the Environmental Protection Agency for Low Carbon Fuel Standard (“LCFS”) and Renewable Identification Number (“RIN”)...

EMERYVILLE, Calif., May 09, 2022 (GLOBE NEWSWIRE) — Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today reported financial results for the quarter ended March 31, 2022. Recent HighlightsDelivered total revenue of $20.2 million for the first quarter of 2022, representing growth of 8.5% year over yearSigned a strategic partnership agreement with Vestaron to develop pesticidal peptides using the Company’s Beacon® platform and proprietary high-throughput, functional screening serviceReleased an upgrade to the Software Suite for Beacon and Lightning® platforms, enabling customers to gain easier insights and faster throughput operations for antibody discovery, cell line development and cell therapy workflowsAppointed Siddhartha Kadia as chief executive officer (CEO) and Lucas Vitale as chief human resources...

Q1 2022 Revenue Increased 20.1% and Shipments Increased 15.3% vs. Q4 2021 NASHVILLE, Tenn., May 09, 2022 (GLOBE NEWSWIRE) — SmileDirectClub, Inc. (Nasdaq: SDC), the next generation oral care company with the first medtech platform for teeth straightening, today announced its financial results for the first quarter ended March 31, 2022. Revenue for the first quarter of 2022 increased 20.1% compared to the fourth quarter of 2021 with gross profit up 32.5% for the same period. First Quarter 2022 Financial HighlightsTotal revenue of $152 million, a 20.1% increase over the fourth quarter of 2021 and a decrease of 24.0% over the prior year period. Net loss of $(73) million, an improvement of $22 million over both the fourth quarter of 2021 and the prior year period. Adjusted EBITDA of $(34) million, a $27 million improvement over...

KORSUVA™ (difelikefalin) injection U.S. commercial launch began in April 2022 and is tracking to expectation Kapruvia® (difelikefalin) approved by European Commission for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients, triggering $15M milestone payment to Cara Top-line data from Phase 2 proof-of-concept trial of Oral KORSUVA (difelikefalin) in notalgia paresthetica expected in 2Q 2022 Oral KORSUVA (difelikefalin) Phase 3 pruritus programs in non-dialysis dependent advanced chronic kidney disease and atopic dermatitis underway Conference call today at 4:30 p.m. ET STAMFORD, Conn., May 09, 2022 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients...

SAN FRANCISCO, May 09, 2022 (GLOBE NEWSWIRE) — Augmedix, Inc. (Nasdaq: AUGX), a leading provider of automated medical documentation and data services, today reported financial results for the three months ended March 31, 2022. Manny Krakaris, Chief Executive Officer of Augmedix, commented, “We are pleased with our start to 2022 as we continue to make meaningful progress on several growth-focused initiatives, as well as extending our relationships with existing customers. Our main focus has been and will continue to be a path towards a completely automated note, and we have made great strides in this respect. We look forward to building upon the groundwork we have laid out to drive additional growth and gross margin expansion. We are excited for what is in store for the remainder of the year and optimistic that Augmedix will continue...